Drug resistance prevalence in human immunodeficiency virus type 1 infected pediatric populations in honduras and el salvador during 1989-2009

Pediatric Infectious Disease Journal

Volumn 30, Issue 5, 2011, Pages

  Holguín, África ^a   Erazo, Karen ^b   Escobar, Gustavo ^b   de Mulder, Miguel ^a   Yebra, Gonzalo ^a   Martín, Leticia ^a   Jovel, Luis Enrique ^b   Castaneda, Luis ^c   Pérez, Elsy ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Hospital Mario Catarino Rivas   (Honduras)

^c Hospital Nacional de Ninos Benjamin Bloom   (El Salvador)

Author keywords

Antiretroviral treatment; Central America; Children; Drug resistance; El Salvador; HIV 1; Honduras; Mutations; Subtypes; Treatment failure

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; DELAYED DIAGNOSIS; DISEASE SEVERITY; EL SALVADOR; FEMALE; GENOTYPE; HONDURAS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; SYMPTOM; VIRUS MUTATION;

ADOLESCENT; ANTI-HIV AGENTS; BLOOD; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; EL SALVADOR; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HONDURAS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION, MISSENSE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 79954874072     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182117289     Document Type: Article

References (42)

1. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(suppl 2):25-36.
2. Barth RE, Tempelman HA, Smelt E, et al. Long-term outcome of children receiving antiretroviral treatment in rural South Africa: substantial virologic failure on first-line treatment. Pediatr Infect Dis J. 2011;30:52-56.
3. Sohn AH, Nuttall JJ, Zhang F. sequencing of antiretroviral therapy in children in low-and middle-income countries. Curr Opin HIV AIDS. 2010;5:54-60.
4. Welch S, Sharland M, Lyall EG, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613.
5. Hamers RL, Smit PW, Stevens W, et al. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009;14:619-629.
6. Yang C, McNulty A, Diallo K, et al. Development and application of a broadly sensitive dried-blood-spot-based genotyping assay for global surveillance of HIV-1 drug resistance. J Clin Microbiol. 2010;48:3158-3164.
7. UNAIDS Report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/documents/20101123_GlobalReport_em.pdf.
8. The Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010. Honduras 2010 country progress report. Available at: http://data.unaids.org/pub/Report/2010/honduras_2010_country_progress_report_es.pdf. Accessed August 3, 2010.
9. Paz-Bailey G, Morales-Miranda S, Jacobson JO, et al. High rates of STD and sexual risk behaviors among Garífunas in Honduras. J Acquir Immune Defic Syndr. 2009;51(suppl 1):S26-S34.
10. The Joint United Nations Programme on HIV/AIDS (UNAIDS), 2010. El Salvador 2010 country progress report. Available at: http://data.unaids.org/pub/Report/2010/elsalvador_2010_country_progress_report_es.pdf. Accessed August 3, 2010.
11. Holguín A, Suñe C, Hamy F, et al. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol. 2006;36:264-271.
12. Plantier JC, Dachraoui R, Lemee V, et al. HIV-1 resistance genotyping on dried serum spots. AIDS. 2005;19:391-397.
13. Yebra G, de Mulder M, del Romero J, et al. HIV-1 non-B subtypes: high transmitted NNRTI-resistance in Spain and impaired genotypic resistance interpretation due to variability. Antiviral Res. 2010;85:409-417.
14. Zhang C, Ding N, Wei JF. Different sliding window sizes and inappropriate subtype references result in discordant mosaic maps and breakpoint locations of HIV-1 CRFs. Infect Genet Evol. 2008;8:693-697.
15. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009;17:138-145.
16. Centers for Disease Control. 1994 revised classification system for HIV infection and expanded survillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1994;43(RR-12):1-10.
17. U.S. Department of Health and Human Services (DHHS), 2008. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed August 3, 2010.
18. World Health Organization (WHO), 2010. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach 2010 revision. Available at: http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf. Accessed August 3, 2010.
19. Yebra G, Holguin A. Epidemiology of drug-resistant HIV-1 transmission in naïve patients in Spain. Med Clin (Barc). 2010;135:561-567.
20. Sagir A, Oette M, Kaiser R, et al. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother. 2007;60:843-848.
21. Wensing AM, van de Vijver DA, Angarano G, et al. SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
22. Wheeler W, Mahle K, Bodnar UR, et al. Antiretroviral drug-resistance mutations and subtypes in drug-naïve persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006. In: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 648.
23. Brennan CA, Yamaguchi J, Devare SG, et al. Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. Transfusion. 2010;50:2707-2712.
24. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico. HIV Med. 2005;6:403-409.
25. Gonsalez CR, Alcalde R, Nishiya A, et al. Drug resistance among chronic HIV-1-infected patients naïve for use of antiretroviral therapy in Sao Paulo city. Virus Res. 2007;129:87-90.
26. Ferreira FG, Pinto JA, Kakehasi FM, et al. Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses. 2010;26:229-232.
27. Castillo J, Comegna M, Quijada W, et al. Surveillance of HIV type 1 drug resistance among naïve patients from Venezuela. AIDS Res Hum Retroviruses. 2009;25:1329-1333.
28. Dilernia DA, Lourtau L, Gomez AM, et al. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS. 2007;21:1355-1360.
29. Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug naïve patients. J Acquir Immune Defic Syndr. 2006;42:506-510.
30. Lama JR, Sanchez J, Suarez L, et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr. 2006;42:501-505.
31. Ahumada-Ruiz S, Flores-Figueroa D, Toala-González I, et al. Analysis of HIV-1 pol sequences from Panama: identification of phylogenetic clusters within subtype B and detection of antiretroviral drug resistance mutations. Infect Genet Evol. 2009;9:933-940.
32. Lloyd B, O'Connell RJ, Michael NL, et al. Prevalence of resistance mutations in HIV-1 infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses. 2008;24:529-535.
33. Murillo W, Paz-Bailey G, Morales S, et al. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol. 2010;49:239-244.
34. de Mulder M, Yebra G, Martín L, et al. Diversidad genética del VIH-1 y resistencia a fármacos en la cohorte de niños infectados por VIH-1 en Madrid. In: II Congreso Nacional GESIDA (Grupo de Estudio del Sida; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica); December 1-3, 2010; Madrid, Spain. Abstract P-123.
35. Delaugerre C, Chaix ML, Blanche S, et al. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology. 2009;6:85.
36. Chakraborty R, Smith CJ, Dunn D, et al. HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 2008;27:457-459.
37. Murillo W, de Rivera IL, Parham L, et al. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med. 2010;11:95-103.
38. Delaugerre C, Warszawski J, Chaix ML, et al. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. J Med Virol. 2007;79:1261-1269.
39. Lynen L, Van Griensven J, Elliott J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr Opin HIV AIDS. 2010;5:1-5.
40. Lara C, Sällberg M, Johansson B, et al. The Honduran human immunodeficiency virus type-1 (HIV-1) epidemic dominated by HIV-1 subtype B as determined by V3 domain sero-and genotyping. J Clin Microbiol. 1996;35:783-784.
41. Renjifo B, Blackard JT, Klaskala W, et al. HIV-1 subtypes B in Honduras. Virus Res. 1999;60:191-197.
42. Onafuwa-Nuga A, Telesnitsky A. The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev. 2009;73:451-480.